-
1Academic Journal
-
2Academic Journal
-
3Academic Journal
Συγγραφείς: Mudunov A.M., Gelfand I.M., Ryzhova O.D., Pak M.B., Tarakanova A.S., Tarakanov, Morozova A.S., Chen H.
Πηγή: Head and Neck Tumors; Vol 15, No 3 (2025); 131-139 ; Опухоли головы и шеи; Vol 15, No 3 (2025); 131-139 ; 2411-4634 ; 2222-1468
Θεματικοί όροι: submandibular gland, ductal adenocarcinoma, epidermal growth factor receptor type 2, distant metastases, trastuzumab, paclitaxel, подчелюстная слюнная железа, протоковая аденокарцинома, рецептор эпидермального фактора роста 2-го типа, отдаленные метастазы, трастузумаб, паклитаксел
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/1112/698; https://ogsh.abvpress.ru/jour/article/view/1112/699; https://ogsh.abvpress.ru/jour/article/view/1112
-
4Academic Journal
Συγγραφείς: A. N. Polyakov, D. V. Podluzhnyi, N. E. Kudashkin, I. S. Bazin, B. M. Medvedeva, A. Yu. Syskova, D. M. Kantieva, Yu. I. Patyutko, А. Н. Поляков, Д. В. Подлужный, Н. Е. Кудашкин, И. С. Базин, Б. М. Медведева, А. Ю. Сыскова, Д. М. Кантиева, Ю. И. Патютко
Πηγή: Research and Practical Medicine Journal; Том 9, № 4 (2022); 114-122 ; Research'n Practical Medicine Journal; Том 9, № 4 (2022); 114-122 ; 2410-1893 ; 10.17709/2410-1893-2022-9-4
Θεματικοί όροι: комбинированное лечение рака поджелудочной железы, ductal adenocarcinoma, local relapse of pancreatic cancer, irreversible electroporation, combined treatment for pancreatic cancer, протоковая аденокарцинома, локальный рецидив рака поджелудочной железы, необратимая электропорация
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/838/517; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/692; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/693; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/694; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/695; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/696; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/697; Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492; Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB 3rd, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Aug 1;34(22):2654–2668. https://doi.org/10.1200/JCO.2016.67.5561; Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol. Clin. Oncol. 2016;4:315– 325. https://doi.org/10.3892/mco.2015.716; Vogel JA, van Veldhuisen E, Agnass P, Crezee J, Dijk F, Verheij J, et al. Time-dependent impact of irreversible electroporation on pancreas, liver, blood vessels and nerves: a systematic review of experimental studies. PLoS ONE. 2016;11(11):e0166987. https://doi.org/10.1371/journal.pone.0166987; Martin RC 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation Safety and Efficacy. Ann Surg 2015;262:486–494. https://doi.org/10.1097/SLA.0000000000001441; Астахов Д. А., Панченков Д. Н., Иванов Ю. В., Шабловский О. Р., Кедрова А. Г., Соловьев Н. А. и др. Необратимая электропорация при местнораспространенном раке поджелудочной железы. Анналы хирургической гепатологии. 2018;23(2):59–68. https://doi.org/10.16931/1995-5464.2018259-68; Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med 2013;369:1691–1703. https://doi.org/10.1056/NEJMoa1304369; Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer N Engl J Med 2011;364:1817–1825. https://doi.org/10.1056/NEJMoa1011923; Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019 May 19;11:1758835919850367. https://doi.org/10.1177/1758835919850367; Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324; Ионкин Д. А., Карельская Н. А., Степанова Ю. А., Земсков В. М., Козлова М. Н., Жаворонкова О. А. и др. Криодеструкция при местнораспространенном раке поджелудочной железы. Анналы хирургической гепатологии. 2018;23(2):37–49. https://doi.org/10.16931/1995-5464.2018237-49; Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Transactions on Bio-medical Engineering 2006;53:1409–1415. https://doi.org/10.1109/TBME.2006.873745; Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, et al. Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma. J Vasc Interv Radiol 2012;23:1613–1621. https://doi.org/10.1016/j.jvir.2012.09.012; https://www.rpmj.ru/rpmj/article/view/838
-
5Academic Journal
Συγγραφείς: D. M. Kuchin, Ya. I. Kolesnik, H. G. Torgomyan, V. E. Zagainov, Д. М. Кучин, Я. И. Колесник, Г. Г. Торгомян, В. Е. Загайнов
Πηγή: Malignant tumours; Том 11, № 1 (2021); 20-28 ; Злокачественные опухоли; Том 11, № 1 (2021); 20-28 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: многофакторный анализ, ductal adenocarcinoma of the pancreas, overall survival, multivariate analysis, протоковая аденокарцинома поджелудочной железы, общая выживаемость
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/827/585; Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2018 // CA: A Cancer Journal for Clinicians. 2018. Vol. 68, № 1. P. 7–30.; Bray F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries// CA: A Cancer Journal for Clinicians. 2018. Vol. 68, № 6. P. 394–424.; Allemani C. et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD- 3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries// The Lancet. 2018. Vol. 391, № 10 125. P. 1023–1075.; Strobel O. et al. Optimizing the outcomes of pancreatic cancer surgery// Nature Reviews Clinical Oncology. Springer US, 2019. Vol. 16, № 1. P. 11–26.; Hackert T. et al. The TRIANGLE operation — radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study// Hpb. International Hepato-Pancreato-Biliary Association Inc., 2017. Vol. 19, № 11. P. 1001–1007.; Bilimoria K. Y. et al. Multimodality therapy for pancreatic cancer in the U. S.: Utilization, outcomes, and the effect of hospital volume// Cancer. 2007. Vol. 110, № 6. P. 1227–1234.; Altman A. M. et al. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival// Annals of Surgical Oncology. Springer International Publishing, 2019. Vol. 26, № 12. P. 4108–4116.; Huang L. et al. Resection of pancreatic cancer in Europe and USA: An international large-scale study highlighting large variations// Gut. 2019. Vol. 68, № 1. P. 130–139.; Luberice K. et al. Has survival improved following resection for pancreatic adenocarcinoma? // American Journal of Surgery. Elsevier Ltd, 2017. Vol. 214, № 2. P. 341–346.; Tian X. et al. Prognostic factors for disease-free survival in patients with pancreatic ductal adenocarcinoma after surgery// Journal of Pancreatology. 2019. Vol. 2, № 1. P. 22–27.; National Comprehensive Cancer Network. Pancreatic Adenocarcinoma Version 2. 2021 — February 25, 2021 URL: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.; Ducreux M. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up// Annals of Oncology. 2015. Vol. 26, № Supplement 5. P. v56 — v68.; Kuchin D.M. et al. Extensive gastropancreatoduodenal resections in the treatment of ductal carcinoma of the head of pancreas // Sovremennye Tehnologii v Medicine. 2012. Vol. 2012, № 3. P. 54–59.; Gillen S. et al. Preoperative / neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages// PLoS Medicine. 2010. Vol. 7, № 4. P. 1–15.; Versteijne E. et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer// British Journal of Surgery. 2018. Vol. 105, № 8. P. 946–958.; Tummers W. S. et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery// British Journal of Surgery. 2019. Vol. 106, № 8. P. 1055–1065.; Imamura T. et al. Prognostic role of the length of tumour — vein contact at the portal — superior mesenteric vein in patients having surgery for pancreatic cancer// British Journal of Surgery. 2019. Vol. 106, № 12. P. 1649–1656.; Ramacciato G. et al. Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients// Annals of Surgical Oncology. 2016. Vol. 23, № 6. P. 2028–2037.; Yu X. Z. et al. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: A meta-analysis// European Journal of Surgical Oncology. 2014. Vol. 40, № 4. P. 371–378.; Prakash L. R. et al. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection// Journal of Gastrointestinal Surgery. Journal of Gastrointestinal Surgery, 2020. Vol. 24, № 2. P. 368–379.; Kim M. et al. Prediction and clinical implications of portal vein / superior mesenteric vein invasion in patients with resected pancreatic head cancer: the significance of preoperative CT parameters// Clinical Radiology. The Royal College of Radiologists, 2018. Vol. 73, № 6. P. 564–573.; Bergquist J. R. et al. Carbohydrate antigen 19–9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: A national cancer database study// Journal of the American College of Surgeons. Elsevier Ltd, 2016. Vol. 223, № 1. P. 52–65.; Reni M. et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma// Annals of Oncology. 2017. Vol. 28, № 11. P. 2786–2792.; Haas M. et al. Prognostic value of CA19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: Results from a multicenter, pooled analysis of patients receiving palliative chemotherapy// Journal of Cancer Research and Clinical Oncology. 2013. Vol. 139, № 4. P. 681–689.; Goh S. K. et al. Serum carbohydrate antigen 19–9 in pancreatic adenocarcinoma: a mini review for surgeons// ANZ Journal of Surgery. 2017. Vol. 87, № 12. P. 987–992.; Kardosh A. et al. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study// Pancreas. 2018. Vol. 47, № 8. P. 958–966.; Tanaka M. et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer // British Journal of Surgery. 2019. Vol. 106, № 12. P. 1590–1601.; https://www.malignanttumors.org/jour/article/view/827
-
6Academic Journal
Συγγραφείς: Nychytailo, M. Yu., Bulyk, I. I., Nazarko, L. R., Horbunov, A. A., Kolesnyk, A. V.
Πηγή: Hospital Surgery. Journal named by L.Ya. Kovalchuk; No. 3 (2017); 93-97 ; Госпитальная хирургия. Журнал имени Л.А. Ковальчука; № 3 (2017); 93-97 ; Шпитальна хірургія. Журнал імені Л. Я. Ковальчука; № 3 (2017); 93-97 ; 2414-4533 ; 1681-2778 ; 10.11603/2414-4533.2017.3
Θεματικοί όροι: groove pancreatitis, chronic pancreatitis, differential diagnosis, surgical treatment, pancreatic adenocarcinoma, парадуоденальный панкреатит, хронический панкреатит, дифференциальная диагностика, хирургическое лечение, протоковая аденокарцинома, парадуоденальний панкреатит, хронічний панкреатит, диференціальна діагностика, хірургічне лікування, про- токова аденокарцинома
Περιγραφή αρχείου: application/pdf
Relation: https://ojs.tdmu.edu.ua/index.php/surgery/article/view/8129/7719; https://ojs.tdmu.edu.ua/index.php/surgery/article/view/8129; https://repository.tdmu.edu.ua//handle/123456789/13202
-
7Academic Journal
Συγγραφείς: L. I. Moskvicheva, L. V. Bolotina, Л. И. Москвичева, Л. В. Болотина
Πηγή: Research and Practical Medicine Journal; Том 7, № 4 (2020); 118-134 ; Research'n Practical Medicine Journal; Том 7, № 4 (2020); 118-134 ; 2410-1893 ; 10.17709/2409-2231-2020-7-4
Θεματικοί όροι: онкология, adenocarcinoma, palliative cancer care, chemotherapy, drug therapy, oncology, протоковая аденокарцинома, паллиативная онкологическая помощь, химиотерапия, лекарственная терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/637/396; McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov 21;24(43):4846–4861. https://doi.org/10.3748/wjg.v24.i43.4846; Состояние онкологической помощи населению России в 2018 году. Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. М.: МНИОИ им. П.А.Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019, 236 с.; Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013 Sep;63(5):318–348. https://doi.org/10.3322/caac.21190; Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017 Dec;6(6):58. https://doi.org/10.21037/cco.2017.12.04; Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019 Aug 8;14(1):141. https://doi.org/10.1186/s13014-019-1345-6; Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci. 2019 Sep 13;20(18):4543. https://doi.org/10.3390/ijms20184543; Милешина С.Е. Противоопухолевые средства. Доступно по: http://do.rsmu.ru/fileadmin/user_upload/pf/protivoopukholevye_sr-va.pdf Дата обращения: 21.06.2020.; Покатаев И.А., Алиева С.Б., Гладков О.А., Загайнов В.Е., Кудашкин Н.Е., Патютко Ю.И. и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO. 2019;3s2(9):456–468. https://doi.org/10.18027/2224-5057-2019-9-3s2-456-468; Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. https://doi.org/10.1200/JCO.1997.15.6.2403; Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017 Jun 22;18(7):E1338. https://doi.org/10.3390/ijms18071338; Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1;31(13):1640–1648. https://doi.org/10.1200/JCO.2012.43.3680; Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007 Jun 1;25(16):2212–2217. https://doi.org/10.1200/JCO.2006.09.0886; Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513–5518. https://doi.org/10.1200/JCO.2009.24.2446; Lee HS, Chung MJ, Park JY, Bang S, Park SW, Kim HG, et al. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore). 2017 Jan;96(1):e5702. https://doi.org/10.1097/MD.0000000000005702; Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006 Aug 20;24(24):3946–3952. https://doi.org/10.1200/JCO.2005.05.1490; Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10;27(23):3778–3785. https://doi.org/10.1200/JCO.2008.20.9007; Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15;22(18):3776–3783. https://doi.org/10.1200/JCO.2004.12.082; Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CAL-GB 80303). J Clin Oncol. 2010 Aug 1;28(22):3617–3622. https://doi.org/10.1200/JCO.2010.28.1386; Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960–1966. https://doi.org/10.1200/JCO.2006.07.9525; Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817– 1825. https://doi.org/10.1056/NEJMoa1011923; Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016 Jun;17(6):801–810. https://doi.org/10.1016/S1470-2045(16)00172-8; JG, de Jesus VHF, Camandaroba MPG, Dettino ALA. Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience. Ther Adv Med Oncol. 2019;11:1-13. https://doi.org/10.1177/1758835919874650; Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013 Jan 1;31(1):23–29. https://doi.org/10.1200/JCO.2012.44.4869; Wang Z-Q, Zhang F, Deng T, Zhang L, Feng F, Wang F-H, et al. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Commun (Lond). 2019 08;39(1):26. https://doi.org/10.1186/s40880-019-0367-7; Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, et al. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol. 2018 Nov 15;10(11):421– 430. https://doi.org/10.4251/wjgo.v10.i11.421; Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369; Tsujimoto A, Sudo K, Nakamura K, Kita E, Hara R, Takayama W, et al. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Sci Rep. 2019 07;9(1):16187. https://doi.org/10.1038/s41598-019-52486-x; Petrillo A, Pappalardo A, Calabrese F, Tirino G, Pompella L, Ventriglia J, et al. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. J Gastrointest Oncol. 2019 Oct;10(5):910–917. https://doi.org/10.21037/jgo.2019.06.02; Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, et al. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. J Cancer. 2019;10(18):4420–4429. https://doi.org/10.7150/jca.29898; Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, et al. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 Aug;9(15):5406–5415. https://doi.org/10.1002/cam4.3229; Charton E, Bachet J-B, Hammel P, Desramé J, Chibaudel B, Cohen R, et al. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. Cancer Med. 2019 Sep;8(11):5079–5088. https://doi.org/10.1002/cam4.2311; Kowalewski A, Szylberg Ł, Saganek M, Napiontek W, Antosik P, Grzanka D. Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol. 2018 Aug;144(8):1503–1507. https://doi.org/10.1007/s00432-018-2666-9; Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014 Sep 9;111(6):1132–1138. https://doi.org/10.1038/bjc.2014.418; Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 25;381(4):317– 327. https://doi.org/10.1056/NEJMoa1903387; Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676–1681. https://doi.org/10.1016/j.ejca.2011.04.011; Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545– 557. https://doi.org/10.1016/S0140-6736(15)00986-1; Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423–2429. https://doi.org/10.1200/JCO.2013.53.6995; Lee MG, Lee SH, Lee SJ, Lee YS, Hwang J-H, Ryu JK, et al. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy. 2013;59(4):273–279. https://doi.org/10.1159/000356158; Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology. 2011;80(5–6):301–306. https://doi.org/10.1159/000329803; Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol. 2019 Nov 15;11(11):1021–1030. https://doi.org/10.4251/wjgo.v11.i11.1021; Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009 Jan;63(2):313–319. https://doi.org/10.1007/s00280-008-0741-7; Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol. 2011 Feb;67(2):249–254. https://doi.org/10.1007/s00280-010-1311-3; Lee K, Bang K, Yoo C, Hwang I, Jeong JH, Chang H-M, et al. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Res Treat. 2020 Jan;52(1):254–262. https://doi.org/10.4143/crt.2019.190; Merz V, Cavaliere A, Messina C, Salati M, Zecchetto C, Casalino S, et al. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers (Basel). 2020 Apr 30;12(5):1131. https://doi.org/10.3390/cancers12051131; Chae H, Jeong H, Cheon J, Chon HJ, Ryu H, Kim I-H, et al. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Ther Adv Med Oncol. 2020;12:1–8. https://doi.org/10.1177/1758835920923424; de Jesus VHF, Camandaroba MPG, Calsavara VF, Riechelmann RP. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. Ther Adv Med Oncol. 2020;12: 1–13. https://doi.org/10.1177/1758835920905408; Buwenge M, Macchia G, Arcelli A, Frakulli R, Fuccio L, Guerri S, et al. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. J Pain Res. 2018;11:2169–2178. https://doi.org/10.2147/JPR.S167994; Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016 May 3;315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324; Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S; Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):317–326. https://doi.org/10.1016/S1470-2045(13)70021-4; Wang C, Liu X, Wang X, Wang Y, Cha N. Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Sep;97(36):e12260. https://doi.org/10.1097/MD.0000000000012260; Хитрова А.Н., Болотина Л.В., Корниецкая А.Л., Москвичева Л.И. Проведение высокоинтенсивной фокусированной ультразвуковой терапии в рамках комбинированного лечения неоперабельной больной раком поджелудочной железы. Онкология. Журнал им. П.А.Герцена. 2020;9(1):50– 54. https://doi.org/10.17116/onkolog2020901150; Neuzillet C, Gaujoux S, Williet N, Bachet J-B, Bauguion L, Colson Durand L, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis. 2018;50(12):1257–1271. https://doi.org/10.1016/j.dld.2018.08.008; Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem J-L, Malka D, et al. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol. 2019;11:1–43. https://doi.org/10.1177/1758835919875568; https://www.rpmj.ru/rpmj/article/view/637
-
8Academic Journal
Συγγραφείς: Tumanskyi, V. O., Kovalenko, I. S.
Πηγή: Pathologia; Vol. 16 No. 1 (2019): Pathologia ; Патология; Том 16 № 1 (2019): Патологія ; Патологія; Том 16 № 1 (2019): Патологія ; 2310-1237 ; 2306-8027
Θεματικοί όροι: pancreatic ductal adenocarcinoma, pancreatic neoplasms, neoplastic stem cells, протоковая аденокарцинома поджелудочной железы, новообразования поджелудочной железы, неопластические стволовые клетки, протокова аденокарцинома підшлункової залози, новоутворення підшлункової залози, неопластичні стовбурові клітини
Περιγραφή αρχείου: application/pdf
Relation: http://pat.zsmu.edu.ua/article/view/166476/167144; http://pat.zsmu.edu.ua/article/view/166476
Διαθεσιμότητα: http://pat.zsmu.edu.ua/article/view/166476
-
9Academic Journal
Πηγή: МОДЕЛИРОВАНИЕ, ОПТИМИЗАЦИЯ И ИНФОРМАЦИОННЫЕ ТЕХНОЛОГИИ. 9:24-25
Θεματικοί όροι: эндоскопическая ультрасонография, chronic pancreatitis, characteristics of the contours of focal formations of the pancreas, ductal adenocarcinoma, хронический панкреатит, statistical analysis, характер контуров очаговых образований поджелудочной железы, протоковая аденокарцинома, статистический анализ, 3. Good health, endoscopic ultrasonography
-
10Academic Journal
Συγγραφείς: Kolesnikova, O. V.
Πηγή: Современная гастроэнтерология; № 6 (2019); 59—67
Сучасна гастроентерологія; № 6 (2019); 59—67
Modern Gastroenterology; № 6 (2019); 59—67Θεματικοί όροι: цукровий діабет 3с типу, хронічний панкреатит, протокова аденокарцинома підшлункової залози, type 3c diabetes mellitus, chronic pancreatitis, pancreatic duct adenocarcinoma, сахарный диабет 3с типа, хронический панкреатит, протоковая аденокарцинома поджелудочной железы, 3. Good health
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://sgastro.com.ua/article/view/MG-2019-6-59
-
11Academic Journal
Συγγραφείς: L. A. Ruiatkina, D. S. Ruiatkin, Л. А. Руяткина, Д. С. Руяткин
Πηγή: Meditsinskiy sovet = Medical Council; № 4 (2018); 28-35 ; Медицинский Совет; № 4 (2018); 28-35 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-4
Θεματικοί όροι: протоковая аденокарцинома поджелудочной железы, type 3c diabetes, chronic pancreatitis, ductal pancreatic adenocarcinoma, сахарный диабет типа 3с, хронический панкреатит
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2328/2311; Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev, 2012 May, 28(4): 338-42. doi:10.1002/dmrr.2260.; Malka D, Hammel P, Sauvanet A, Rufat P, O’Toole D, Bardet P, Belghiti J, Bernades P, Ruszniewski P, Lévy P. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology, 2000 Nov, 119(5): 1324-32.; Angelopoulos N, Dervenis C, Goula A, Rombopoulos G, Livadas S, Kaltsas D, Kaltzidou V, Tolis G. Endocrine pancreatic insufficiency in chronic pancreatitis. Pancreatology, 2005, 5(23): 122-31. doi:10.1159/000085264; Choudhuri G1, Lakshmi CP, Goel A. Pancreatic diabetes. Trop Gastroenterol, 2009 Apr-Jun, 30(2): 71-5.; Perusicová J. Diabetes mellitus in chronic pancreatitis. Vnitr Lek, 2004 May, 50(5): 375-8.; American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2006 Jan, 29(suppl 1): 43-48.; American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2011 Jan, 34(Suppl 1): 62–69.doi:10.2337/dc11-S062.; Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, Brand R, Frulloni L, Anderson MA, Whitcomb DC. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. PancreasFest Recommendation Conference Participants. Pancreatology, 2013, 13(4): 336-42. doi:10.1016/j.pan.2013.05.002.; Phil A Hart, Melena D Bellin, Dana K Andersen, David Bradley, Zobeida Cruz-Monserrate, Christopher E Forsmark, Mark O Goodarzi, Aida Habtezion, Murray Korc, Yogish C Kudva, Stephen J Pandol, Dhiraj Yadav, and Suresh T Chari, on behalf of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC). Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol, 2016 Nov, 1(3): 226–237. doi:10.1016/S2468-1253(16)30106-6.; Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol, 2013, 19(42): 7276-7281.; Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й выпуск. Сахарный диабет, 2017, 20(1S): 1-112. doi:10.14341/DM20171S8; Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology, 2011, 11(3): 279-94. doi:10.1159/000329188.; Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, Shimosegawa T. Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition. Pancreatology, 2016 Mar-Apr, 16(2): 218-24. doi:10.1016/j.pan.2016.02.001.; Sheth SG, Conwell DL, Whitcomb DC, Alsante M, Anderson MA, Barkin J, Brand R, Cote GA, Freedman SD, Gelrud A, Gorelick F, Lee LS, Morgan K, Pandol S, Singh VK, Yadav D, Wilcox CM, Hart PA. Academic Pancreas Centers of Excellence: Guidance from a multidisciplinary chronic pancreatitis working group at PancreasFest. Pancreatology, 2017, 17(3): 419430. doi:10.1016/j.pan.2017.02.015.; Struyvenberg MR, Martin CR, Freedman SD. Practical guide to exocrine pancreatic insufficiency -Breaking the myths. BMC Med, 2017 Feb 10, 15(1): 29. doi:10.1186/s12916-017-0783-y.; Singh VK, Haupt ME, Geller DE, Hall JA, Quintana Diez. Less common etiologies of exocrine pancreatic insufficiency. World J Gastroenterol, 2017 Oct 21, 23(39): 7059-7076. doi:10.3748/wjg.v23.i39.7059.; Lew D, Afghani E, Pando S. Chronic Pancreatitis: Current Status and Challenges for Prevention and Treatment. Dig Dis Sci, 2017, 62(7): 1702– 1712. doi:10.1007/s10620-017-4602-2.; Gudipaty L and Rickels MR. Pancreatogenic (Type 3c) Diabetes. Pancreapedia: Exocrine Pancreas Knowledge Base. 2015. doi:10.3998/panc.2015.35.; Ребров А.П., Куницына М.А., Кашкина Е.И., Архангельская Е.Е. Панкреатогенный сахарный диабет: актуальные проблемы патогенеза и лечения (обзор). Саратовский научномедицинский журнал, 2012, 8(3): 862-867.; Niebisz-Cieślak AB and Karnafel W. Insulin sensitivity in chronic pancreatitis and features of insulin resistance syndrome. Pol Arch Med Wewn, 2010, 120: 255–263.; Brereton MF, Vergari E, Zhang Q, Clark A. Alpha-, Deltaand PP-cells: Are They the Architectural Cornerstones of Islet Structure and Co-ordination? J Histochem Cytochem, 2015 Aug, 63(8): 575–591. doi:10.1369/0022155415583535.; Прощина А.Е., Кривова Ю.С., Барабанов В.М., Савельев С.В. Иммуногистохимическое исследование наиболее крупных островков поджелудочной железы человека при старении и при сахарном диабете 1 и 2 типов, перспективы для трансплантации. Сахарный диабет, 2013, (4): 38–43.; Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis, aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol, 2010, 24: 349–358. doi:10.1016/j.bpg.2010.02.007.; Andersen DK, Andren-Sandberg A, Duell EJ, et al. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas, 2013, 42: 1227–1237. doi:10.1097/MPA.0b013e3182a9ad9d.; Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas, 2011, 40(3): 339–351. doi:10.1097/MPA.0b013e318209e05d; Eibl G, Cruz-Monserrate Z, Korc M, Petrov MS, Goodarzi MO, Fisher WE, Habtezion A, Lugea A, Pandol SJ, Hart PA, Andersen DK, Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. J Acad Nutr Diet, 2017 Sep 11, pii: S2212-2672(17)31087-0. doi:10.1016/j.jand.2017.07.005.; Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c) Are we neglecting an important disease? Eur J Intern Med, 2013, 24: 203-206. PMID: 23375619.; Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, Chari ST, Abbruzzese J L. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes, 2017 May, 66(5): 1103-1110. doi:10.2337/db16-1477.; Singer MV, Gyr K, Sarles H. Revised classification of pancreatitis. Gastroenterology, Report of the Second International Symposium on the classification of pancreatitis in Marseille, France. March 28–30, 1984, 1985: 683–685.; Yadav D, O’Connell M, Papachristou GI. Natural history following the first attack of acute pancreatitis. Am J Gastroenterol, 2012, 107: 1096– 1103. doi:10.1038/ajg.2012.126.; Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B, CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care, 2010 Dec, 33(12): 2697-708. doi:10.2337/dc10-1768.; Makuc J. Management of pancreatogenic diabetes: challenges and solutions. Diabetes Metab Syndr Obes, 2016, 9: 311–315. doi:10.2147/DMSO.S99701.; Irving HM, Samokhvalov AV, Rehm J. Alcohol as a risk factor for pancreatitis. A systematic review and meta-analysis. JOP, 2009, 10: 387–392.; Samokhvalov AV, Rehm J, Roerecke M. Alcohol consumption as a risk factor for acute and chronic pancreatitis: a systematic review and a series of meta-analyses. EBioMedicine, 2015, 2: 1996–2002. doi:10.1016/j.ebiom.2015.11.023.; Setiawan VW, Pandol SJ, Porcel J, et al. Prospective study of alcohol drinking, smoking, and pancreatitis: the multiethnic cohort. Pancreas, 2016, 45: 819–825.; Sikkens EC, Cahen DL, Koch AD, Braat H, Poley JW, Kuipers EJ, Bruno MJ. The prevalence of fatsoluble vitamin deficiencies and a decreased bone mass in patients with chronic pancreatitis. Pancreatology, 2013, 13: 238–242. DOI:10.1016/j.pan.2013.02.008.; Conlon KC, Duggan SN. Pancreatogenic Type 3c Diabetes: Underestimated, Underappreciated and Poorly Managed. Practical gastroenterology, 2017, serias#163. med.virginia.edu. https://med.virginia.edu/ginutrition/wp-content/ uploads/sites/199/2014/06/Parrish-May-17.pdf.; De-madaria E, Abad-gonzález A, Aparicio JR, et al. The Spanish Pancreatic Club’s recommendations for the diagnosis and treatment of chronic pancreatitis: part 2 (treatment). Pancreatology. 2013, 13: 18–28. doi: http://dx.doi.org/10.1016/j.pan.2012.11.310.; Bellin MD, Freeman ML, Gelrud A, et al. Total pancreatectomy and islet auto transplantation in chronic pancreatitis: recommendations from PancreasFest. Pancreatology, 2014, 14: 27–35.; Knop FK, Vilsbøll T, Larsen S, Højberg PV, Vølund A, Madsbad S, Holst JJ, Krarup T. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab, 2007 Jan, 292(1): E324-30. DOI:10.1152/ajpendo.00059.2006.; Meier JJ, Giese A Diabetes associated with pancreatic diseases. Curr Opin Gastroenterol, 2015 Sep, 31(5): 400-6. doi:10.1097/MOG.0000000000000199.; Das S, Tripathy SK, Panda BP. Pancreatic Diabetes. Medicine Update, 2017. Section 18: Diabetes, 757-761. https: //issuu.com/urvitrivedi/docs/18_diabetes/1?ff=true.; Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009 Jan, 32(1): 193-203.; Руяткина Л.А., Руяткин Д.С. Многоплановые эффекты метформина у пациентов с сахарным диабетом 2 типа. Сахарный диабет, 2017, 20(3): 210-219. doi:10.14341/DM8676.; Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu J, Ren ZG, Jiang GL. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract, 2014 Oct, 106(1): 19-26. doi:10.1016/j.diabres.2014.04.007.; Dong YW, Shi YQ, He LW, Cui XY, Su PZ. Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis. Oncotarget, 2017 May 26, 8(33): 55478-55488. doi:10.18632/oncotarget.18233.; Kowall B, Rathmann W, Kostev K. Are Sulfonylurea and Insulin Therapies Associated With a Larger Risk of Cancer Than Metformin Therapy? A Retrospective Database Analysis. Diabetes Care, 2015, 38(1): 59-65.; Li X, Li T, Liu Z, Gou S, Wang C The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Sci Rep, 2017 Jul 19, 7(1): 5825. doi:10.1038/s41598-017-06207-x.; Yang JY, Kweon MN. The gut microbiota: a key regulator of metabolic diseases. BMB Rep, 2016 Oct, 49(10): 536-541.; Hur KY, Lee MS. New mechanisms of metformin action: Focusing on mitochondria and the gut. J Diabetes Investig, 2015, 6(6): 600–609. doi:10.1111/jdi.12328.; Jandhyala SM, Madhulika A, Deepika G, Rao GV, Reddy DN, Subramanyam C, Sasikala M, Talukdar R. Altered intestinal microbiota in patients with chronic pancreatitis: implications in diabetes and metabolic abnormalities. Scientific Reports, 2017, 3(7): 43640. doi:10.1038/srep43640.; Tilg H, Moschen AR. Microbiota and Diabetes: An Evolving Relationship. Gut, 2014, 63(9): 1513-21. doi:10.1136/gutjnl-2014-306928.; Sola D, Rossi L, Schianca GPC, Maffioli P, Bigliocca M, Mella R, Corlianò F, Fra G.P, Bartoli E, and Derosa G. Sulfonylureas and their use in clinical practice. Arch Med Sci, 2015 Aug 12, 11(4): 840–848. doi:10.5114/aoms.2015.53304.; Lee YH, Lee BW, Chun SW, Cha BS, Lee HC. Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure. Int J Clin Pract, 2011 Oct, 65(10): 1076-84. doi:10.1111/j.1742-1241.2011.02755.; Knop FK. Incretin hormones and beta cell function in chronic pancreatitis. Dan Med Bull, 2010 Jul, 57(7): B4163.; Iyer SN, Tanenberg RJ, Mendez CE, West RL, Drake AJ .Pancreatitis associated with incretinbased therapies. Diabetes Care, 2013 Apr, 36(4): e49. doi:10.2337/dc12-1987.; Egan A, et al. Pancreatic safety of incretinbased drugs – FDA and EMA assessment. N Engl J Med, 2014, 370: 794–6.; Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med, 2012, 367(4): 319-328.; Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: A consensus report. Diabetes Care, 2010, 33(7): 1674-1685.
-
12Academic Journal
Πηγή: Medical Visualization; № 4 (2016); 54-63 ; Медицинская визуализация; № 4 (2016); 54-63 ; 2408-9516 ; 1607-0763
Θεματικοί όροι: differential diagnosis, протоковая аденокарцинома поджелудочной железы, опухоли поджелудочной железы солидной структуры, дифференциальная диагностика, MDCT, pancreatic ductal adenocarcinoma, solid pancreatic lesion
Περιγραφή αρχείου: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/297/298; Sachs T., Pratt W.B., Callery M.P., Vollmer C.M. Jr. The Incidental Asymptomatic Pancreatic Lesion: Nuisance or Threat? J. Gastrointest. Surg. 2009; 13 (3): 405-415.; Winter J.H., Cameron J.L., Lillemoe K.D. et al. Periampullary and pancreatic incidentaloma: A single institution’s experience with an increasingly common diagnosis. Ann. Surg. 2006; 243; 5: 673-683.; Lahat G., Ben Haim M., Nachmany I. et al. Pancreatic incidentalomas: high rate of potentially malignant tumors. J. Am. Coll. Surg. 2009; 209: 313-319.; Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J. Clin. 2001; 51 (1): 15-36.; Ries L.A.G., Kosary C.L., Hankey B.F. et al. SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute, 1999.; Jemal A., Siegel R., Ward E. et al. Cancer statistics 2009. CA Cancer J. Clin. 2009; 59: 225-249.; Паклина О.В., Кармазановский Г.Г., Сетдикова Г.Р. Патоморфологическая и лучевая диагностика хирургических заболеваний поджелудочной железы. М.: Видар-М, 2014. 188 с.; Egorov V.I., Petrov R.V., Solodinina E.N. et al. Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability. Wld J. Gastrointest. Surg. 2013; 5 (4): 83-96.; Осипова Н.Ю., Кармазановский Г.Г., Старков Ю.Г., Солодинина Е.Н. Магнитно-резонансная холангиопанкреатография и интраоперационные методы диагностики холедохолитиаза. Медицинская визуализация. 2004; 5: 29-35.; Белоусова Е.Л., Кармазановский Г.Г., Кубышкин В.А. и др. КТ-признаки, позволяющие определить оптимальную тактику лечения при нейроэндокринных опухолях поджелудочной железы. Медицинская визуализация. 2015; 5: 73-82.; Madan A.K., Weldon C.B., Long W.P. et al. Solid and papillary epithelial neoplasms of the pancreas. J. Surg. Oncol. 2004. 85:193-198.; Crippa S., Angelini C., Mussi C. et al. Surgical Treatment of Metastatic Tumors to the Pancreas: A Single Center Experience and Review of the Literature. Wld J. Surg. 2006; 30: 1536.; Hung J.H., Wang S.E., Shyr Y.M. et al. Resection for Secondary Malignancy of the Pancreas. Pancreas. 2012; 41 (1): 121-129.; Tanis P.J., van der Gaag N.A., Busch O.R. et al. Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br. J. Surg. 2009; 96: 579-592.; Takahashi N., Fletcher J.G., Fidler J.L. et al. Dual-phase CT of autoimmune pancreatitis: a multireader study. Am. J. Roentgenol. 2008, 190: 280-286.; https://medvis.vidar.ru/jour/article/view/297
Διαθεσιμότητα: https://medvis.vidar.ru/jour/article/view/297
-
13Academic Journal
Συγγραφείς: ПАКЛИНА О.В., СЕТДИКОВА Г.Р., ЧЕКМАРЕВА И.А.
Περιγραφή αρχείου: text/html
-
14Academic Journal
Συγγραφείς: СЕТДИКОВА Г.Р., ПАКЛИНА О.В., ШАБУНИН А.В., БЕДИН В.В., ТАВОБИЛОВ М.М., ХАТЬКОВ И.Е., ИЗРАИЛОВ Р.Е.
Θεματικοί όροι: ПРОТОКОВАЯ АДЕНОКАРЦИНОМА,ПОДЖЕЛУДОЧНАЯ ЖЕЛЕЗА,РАСПРОСТРАНЕНИЕ ПРОТОКОВОГО РАКА,DUCTAL ADENOCARCINOMA,PANCREAS
Περιγραφή αρχείου: text/html
-
15Academic Journal
Συγγραφείς: Бегалиев, А. Т.
Θεματικοί όροι: клинико-лобараторные проявления, протоковая аденокарцинома, нейроэндокринные опухоли головки поджелудочной железы
Relation: Бегалиев, А. Т. Клинико-лобараторные проявления протоковой аденокарциномы и нейроэндокринных опухолей головки поджелудочной железы [Электронный ресурс] / А. Т. Бегалиев // Проблемы и перспективы развития современной медицины : сб. науч. ст. XIV Респ. науч.-практ. конф. с междунар. участием студентов и молодых ученых, Гомель, 5-6 мая 2022 г. : в 6 т. / Гомел. гос. мед. ун-т; редкол. : И. О. Стома [и др.]. – Гомель : ГомГМУ, 2022. – Т. 5. – С. 99–101. – 1 электрон. опт. диск (CD-ROM). Научный руководитель: к.м.н., доцент И. В. Михайлов; http://elib.gsmu.by/handle/GomSMU/12044
Διαθεσιμότητα: http://elib.gsmu.by/handle/GomSMU/12044
-
16Academic Journal
Πηγή: Российский медико-биологический вестник имени академика И.П. Павлова.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, ХРОНИЧЕСКИЙ ПАНКРЕАТИТ,ПРОТОКОВАЯ АДЕНОКАРЦИНОМА,ТОЛСТОИГОЛЬНАЯ БИОПСИЯ,КРИОСТАТНЫЙ СРЕЗ,CHRONIC PANCREATITIS,DUCTAL ADENOCARCINOMA,CORE-BIOPSY,CRYOSTAT SECTIONS, 3. Good health
Περιγραφή αρχείου: text/html
-
17Academic Journal
Συγγραφείς: Чесноков, Михаил, Кустова, И., Шавочкина, Д., Кузнецова, А., Лазаревич, Н.
Θεματικοί όροι: ПРОТОКОВАЯ АДЕНОКАРЦИНОМА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ, HNF4α, ИЗОФОРМЫ, ЭКЗОГЕННАЯ ЭКСПРЕССИЯ, УРОВЕНЬ ДИФФЕРЕНЦИРОВКИ
Περιγραφή αρχείου: text/html
-
18Academic Journal
Συγγραφείς: Сетдикова, Галия, Паклина, Оксана, Израилов, Роман, Цыганов, Сергей
Θεματικοί όροι: ПРОТОКОВАЯ АДЕНОКАРЦИНОМА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ, ГЕНЫ СУПРЕССОРЫ ОПУХОЛЕВОГО РОСТА, Р16, Р53, МЕТАСТИН
Περιγραφή αρχείου: text/html
-
19Academic Journal
Πηγή: Российский медико-биологический вестник имени академика И.П. Павлова.
Θεματικοί όροι: ПРОТОКОВАЯ АДЕНОКАРЦИНОМА,ПОДЖЕЛУДОЧНАЯ ЖЕЛЕЗА,РАСПРОСТРАНЕНИЕ ПРОТОКОВОГО РАКА,DUCTAL ADENOCARCINOMA,PANCREAS, 03 medical and health sciences, 0302 clinical medicine, 3. Good health
Περιγραφή αρχείου: text/html
-
20Academic Journal
Πηγή: Российский биотерапевтический журнал.
Θεματικοί όροι: 0301 basic medicine, 03 medical and health sciences, 0302 clinical medicine, ПРОТОКОВАЯ АДЕНОКАРЦИНОМА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ, HNF4α, ИЗОФОРМЫ, ЭКЗОГЕННАЯ ЭКСПРЕССИЯ, УРОВЕНЬ ДИФФЕРЕНЦИРОВКИ
Περιγραφή αρχείου: text/html
